乳腺癌患者血清中巨噬细胞移动抑制因子的临床意义  

Serum levels of macrophage migration inhibitory factor in patients with breast cancer and its clinical significance

作　　者：徐向东[1] 汪波[2] 姚陈[1] 林颖[1] 王深明[1] 

机构地区：[1]中山大学附属第一医院乳腺病治疗中心,广州510080 [2]中山大学附属第一医院检验科,广州510080

出　　处：《中华普通外科学文献（电子版）》2011年第2期38-39,53,共3页Chinese Archives of General Surgery(Electronic Edition)

摘　　要：目的探讨乳腺癌患者血清巨噬细胞移动抑制因子(MIF)水平与其临床特征的关系。方法收集2006年10月至2007年3月乳腺癌患者54例和体检正常的女性健康对照46例血清,用酶联免疫吸附法检测血清MIF、白细胞介素8(IL-8)及血管内皮生长因子(VEGF)的浓度,分析其与临床特征的关系。结果乳腺癌组血清MIF、IL-8及VEGF浓度均明显高于健康对照组(P<0.05),MIF与肿瘤的分期和淋巴结转移相关(P<0.05),乳腺癌组患者血清MIF与IL-8相关(r=0.612,P<0.01)。结论 MIF可能参与了乳腺癌的疾病进展过程,可作为反应肿瘤侵袭的一个有用的生物标记物。Objective To study the relationship between serum macrophage migration inhibitory factor （MIF） levels and clinical features in the patients with breast cancer. Methods Enzyme-linked immunosorbent assay was used to detect the concentration of MIF, IL-8 and VEGF in sera of 54 patients with breast cancer and 46 healthy controls from October 2006 to March 2007. The relationship between serum MIF, IL-8 and VEGF levels and clinical features was analyzed. Results The levels of MIF, IL-8 and VEGF in the sera of patients with breast cancer were signifieandy increased compared to healthy controls（P〈0.05）. The levels of MIF in breast cancer were significantly correlated with clinical progression pathology stages（P〈0.05） and lymph node metastasis（P〈0.05）. Serum MIF levels correlated positively with serum IL-8 levels （r=0.612, P〈0.01）. Conclusion MIF may be involved in the progression of breast cancer and serum MIF may be a useful biological marker of tumor invasiveness for patients with breast cancer.

关 键 词：乳腺癌 巨噬细胞移动抑制因子 IL-8 VEGF 

分 类 号：R737.9[医药卫生—肿瘤]